Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Living Cell Technologies ( (AU:1AI) ) is now available.
Algorae Pharmaceuticals has invited shareholders and investors to an online webinar where Executive Chairman David Hainsworth will outline the company’s current priorities, operational progress and outlook for the second quarter of 2026. Scheduled for 28 April, the event signals the company’s bid to deepen engagement with the market, provide greater visibility on its AI-driven R&D and commercial strategies, and update stakeholders on how these initiatives may shape its near-term trajectory.
More about Living Cell Technologies
Algorae Pharmaceuticals Ltd is an AI-enabled pharmaceutical company focused on drug-combination discovery and pharmaceutical commercialisation. Its proprietary AlgoraeOS platform uses artificial intelligence to identify synergistic drug combinations and guide preclinical experimental design, while its AlgoraeRx division licenses and supplies generic and specialty medicines across Australia and New Zealand through established partners and distribution channels.
YTD Price Performance: -14.29%
Average Trading Volume: 1,986,284
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$24.28M
For an in-depth examination of 1AI stock, go to TipRanks’ Overview page.